Interleukin 23 versus interleukin 12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network,Journal of the American Academy of Dermatology

当前位置： X-MOL 学术 › J. Am. Acad. Dermatol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Interleukin 23 versus interleukin 12/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network
Journal of the American Academy of Dermatology ( IF 12.8 ) Pub Date : 2024-07-28 , DOI: 10.1016/j.jaad.2024.07.1473
Sung Huang Laurent Tsai , Chi-Ya Yang , An-Ping Huo , James Cheng-Chung Wei

Managing psoriasis (PsO) and its comorbidities, particularly psoriatic arthritis, often involves using interleukin (IL)-23 and IL-12/23 inhibitors. However, the comparative risk of these treatments still needs to be explored.

中文翻译：

白细胞介素 23 与白细胞介素 12/23 抑制剂预防银屑病患者偶发性银屑病关节炎的比较？来自 TriNetX 全球协作网络的真实比较

管理银屑病（PsO）及其合并症，尤其是银屑病关节炎，通常涉及使用白细胞介素（IL）-23 和 IL-12/23 抑制剂。然而，这些治疗的相对风险仍有待探索。

更新日期：2024-07-28

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南